Active, not recruitingPhase 3NCT05144256
A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Regularly Transfused, Followed by a 5-Year Extension Period
Studying Disorder of glycolysis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Agios Pharmaceuticals, Inc.
- Principal Investigator
- Medical AffairsAgios Pharmaceuticals, Inc.
- Intervention
- Mitapivat(drug)
- Enrollment
- 49 enrolled
- Eligibility
- 1-17 years · All sexes
- Timeline
- 2022 – 2029
Study locations (22)
- Phoenix Children's Hospital, Phoenix, Arizona, United States
- Stanford Medicine, Palo Alto, California, United States
- Children's Healthcare of Atlanta - Emory, Atlanta, Georgia, United States
- Boston Children's Hospital, Boston, Massachusetts, United States
- Cure 4 the Kids Foundation, A Division of Roseman University of Health Sciences, Las Vegas, Nevada, United States
- Weill Cornell Medical College, New York, New York, United States
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- UT Southwestern Medical Center, Dallas, Texas, United States
- Texas Children's Hospital, Houston, Texas, United States
- Comprehensive Hemophilia Care Clinic at CHEO (Children's Hospital Eastern Ontario), Ottawa, Ontario, Canada
- Fakultní Nemocnice Olomouc, Olomouc, Czechia
- Aarhus University Hospital, Aarhus, Central Jutland, Denmark
- Rigshospitalet, Copenhagen, Denmark
- Charite - UB - CVK - Medizinische Klinik, Berlin, Germany
- Universitair Medisch Centrum Utrecht, Utrecht, Netherlands
- +7 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05144256 on ClinicalTrials.govOther trials for Disorder of glycolysis
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE3NCT05175105A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not Regularly Transfused, Followed by a 5-Year Extension PeriodAgios Pharmaceuticals, Inc.
- ACTIVE NOT RECRUITINGNCT04902833Acquired Pyruvate Kinase Deficiency In Clonal Myeloid NeoplasmsMassachusetts General Hospital
- ACTIVE NOT RECRUITINGNCT03481738Pyruvate Kinase Deficiency Global Longitudinal RegistryAgios Pharmaceuticals, Inc.